UNTERNEHMENSDATEN
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stel …
KURSVERLAUF
1T
+0,6 %
1W
-11,9 %
1M
-15,8 %
6M
-41,6 %
YTD
-39,6 %
1J
-68,4 %
2J
-73,3 %
5J
–
10J
–
FRAG DIE AGENTEN ZU ALVO
Keine Anlageberatung. Für die vollständige Analyse-Übersicht: zur Analyse-Seite →
ANALYSTEN-EINSCHÄTZUNG
KURSZIEL TIEF
5,00 $
KONSENS
8,60 $
MEDIAN
10,00 $
KURSZIEL HOCH
10,00 $
0
STRONG BUY
2
BUY
2
HOLD
1
SELL
0
STRONG SELL
5
GESAMT · Buy
| DATUM | ANALYSTENHAUS | RATING | AKTION |
|---|---|---|---|
| 24.03.2026 | Barclays | Underweight | maintain |
| 24.03.2026 | UBS | Buy | maintain |
| 18.11.2025 | UBS | Buy | maintain |
| 04.11.2025 | Deutsche Bank | Buy → Hold | downgrade |
| 14.10.2025 | Morgan Stanley | Equal Weight → Overweight | upgrade |
| 23.09.2025 | Deutsche Bank | Hold → Buy | upgrade |
| 18.07.2025 | UBS | Buy | maintain |
| 25.07.2024 | Barclays | Overweight | maintain |
KENNZAHLEN
KGV
-10,9
KBV
-3,63
EV/EBITDA
47,12
EIGENKAPITALRENDITE
-0,4 %
NETTOMARGE
1 %
VERSCHULDUNG (D/E)
-5,16
DIVIDENDENRENDITE
0 %
STAND
31.03.2026
FREE FLOAT & LIQUIDITÄT
STREUBESITZ
30,5 %
AKTIEN IM STREUBESITZ
103.215.273
Ø TAGESVOLUMEN (30T)
854.386
INVESTIERTE FONDS
| FONDS / INSTITUTION | ANTEILE | VERÄNDERUNG | STAND |
|---|---|---|---|
| Tempus Wealth Planning, LLC | 0 | -44.213 | 30.06.2026 |
| Bracebridge Capital, LLC | 2.705.304 | +0 | 31.03.2026 |
| MILLENNIUM MANAGEMENT LLC | 2.122.596 | +1.765.420 | 31.03.2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.397.107 | -37.046 | 31.03.2026 |
| LITTLEJOHN & CO LLC | 1.318.534 | +0 | 31.03.2026 |
Keine Anlageberatung. Vergangene Wertentwicklung ist kein Indikator für zukünftige Ergebnisse.